Structure driven design of novel human Ether-A-Go-Go-Related-Gene channel (hERG1) activators

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Guo, Jiqing ^a   Durdagi, Serdar ^a,b   Changalov, Mohamed ^a   Perissinotti, Laura L ^a   Hargreaves, Jason M ^a   Back, Thomas G ^a   Noskov, Sergei Y ^a   Duff, Henry J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b BAHCESEHIR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOFETILIDE; NS 1643; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG1; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; 1,3-BIS(2-HYDROXY-5-TRIFLUOROMETHYLPHENYL)UREA; CARBANILAMIDE DERIVATIVE; CRESOL; ERG1 POTASSIUM CHANNEL; LIGAND; MOLECULAR LIBRARY; PROTEIN BINDING;

ACTION POTENTIAL; ADULT; ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ELECTROPHYSIOLOGY; ENZYME ACTIVE SITE; FETUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; QUANTUM MECHANICS; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG DATABASE; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; SYNTHESIS;

ACTION POTENTIALS; BINDING SITES; CRESOLS; DATABASES, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PHENYLUREA COMPOUNDS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES;

EID: 84924601570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105553     Document Type: Article

References (35)

1. Seebohm G (2005) Activators of cation channels: Potential in treatment of channelopathies. Mol Pharmacol 67: 585-588.
2. Fernandez D, Sargent J, Sachse FB, Sanguinetti MC (2008) Structural basis for ether-a-go-go-related gene K+ channel subtype-dependent activation by niflumic acid. Mol Pharmacol 73: 1159-1167.
3. Smith PL, Baukrowitz T, Yellen G (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-836.
4. Sanguinetti M (2014) HERG1 channel agonists and cardiac arrhythmia. Curr Opin Pharmacol 15: 22-27.
5. Asayama M, Kurokawa J, Shirakawa K, Okuyama H, Kagawa T, et al. (2013) Effects of an hERG Activator, ICA-105574, on Electrophysiological Properties of Canine Hearts. Journal of Pharmacological Sciences 121: 1-8.
6. Casis O, Olesen SP, Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Molecular Pharmacology 69: 658-665.
7. Durdagi S, Guo JQ, Lees-Miller JP, Noskov SY, Duff HJ (2012) Structure- Guided Topographic Mapping and Mutagenesis to Elucidate Binding Sites for the Human Ether-a-Go-Go-Related Gene 1 Potassium Channel (KCNH2) Activator NS1643. Journal of Pharmacology and Experimental Therapeutics 342: 441-452.
8. Hansen RS, Diness TG, Demnitz J, Olesen SP, Grunnet M (2005) NS1643 is a new activator of HERG potassium channels. Circulation 112: U87-U87.
9. Garg V, Stary-Weinzinger A, Sachse F, Sanguinetti MC (2011) Molecular Determinants for Activation of Human Ether-a-go-go-related Gene 1 Potassium Channels by 3-Nitro-N-(4-phenoxyphenyl) Benzamide. Molecular Pharmacology 80: 630-637.
10. Kang JS, Chen XL, Wang HG, Ji JZ, Cheng H, et al. (2005) Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Molecular Pharmacology 67: 827-836.
11. Perry M, Sachse FB, Sanguinetti MC (2007) Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proceedings of the National Academy of Sciences of the United States of America 104: 13827- 13832.
12. Grunnet M, Abbruzzese J, Sachse FB, Sanguinetti MC (2011) Molecular Determinants of Human ether-a-go-go-Related Gene 1 (hERG1) K+ Channel Activation by NS1643. Molecular Pharmacology 79: 1-9.
13. Bilet A, Bauer CK (2012) Effects of the Small Molecule HERG Activator NS1643 on Kv11.3 Channels. PloS One 7: E50886.
14. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, et al. (2012) hERG K+ Channels: Structure, Function and Clinical Significance. Physiological Reviews 92: 1393-1478.
15. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
16. Tristani-Firouzi M, Chen J, Sanguinetti MC (2002) Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of HERG K+ channels. Journal of Biological Chemistry 277: 18994-19000.
17. Durdagi S, Deshpande S, Duff HJ, Noskov SY (2012) Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding. J Chem Inf Model 52: 2760-2774.
18. Subbotina J, Yarov-Yarovoy V, Lees-Miller J, Durdagi S, Guo JQ, et al. (2010) Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. Proteins-Structure Function and Bioinformatics 78: 2922-2934.
19. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177- 6196.
20. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible ligand docking. Abstracts of Papers of the American Chemical Society 214: 154-COMP.
21. Maestro v (2007). Portland, OR: Schrodinger.
22. Lees-Miller JP, Subbotina JO, Guo JQ, Yarov-Yarovoy V, Noskov SY, et al. (2009) Interactions of H562 in the S5 Helix with T618 and S621 in the Pore Helix Are Important Determinants of hERG1 Potassium Channel Structure and Function. Biophys J 96: 3600-3610.
23. Guo JQ, Zhan S, Lees-Miller JP, Teng GQ, Duff HJ (2005) Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm 2: 860-866.
24. Durdagi S, Deshpande S, Duff HJ, Noskov SY (2012) Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding. Journal of Chemical Information and Modeling 52: 2760-2774.
25. Durdagi S, Duff HJ, Noskov SY (2011) Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain. J Chem Inf Model 51: 463-474.
26. Zachariae U, Giordanetto F, Leach AG (2009) Side Chain Flexibilities in the Human Ether-a-go-go Related Gene Potassium Channel (hERG) Together with Matched-Pair Binding Studies Suggest a New Binding Mode for Channel Blockers. Journal of Medicinal Chemistry 52: 4266-4276.
27. Carvalho JFS, Louvel J, Doornbos MLJ, Klaasse E, Yu ZY, et al. (2013) Strategies To Reduce hERG K+ Channel Blockade. Exploring Heteroaromaticity and Rigidity in Novel Pyridine Analogues of Dofetilide. Journal of Medicinal Chemistry 56: 2828-2840.
28. Bentzen BH, Bahrke S, Wu K, Larsen AP, Odening KE, et al. (2011) Pharmacological Activation of Kv11.1 in Transgenic Long QT-1 Rabbits. Journal of Cardiovascular Pharmacology 57: 223-230.
29. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, et al. (2013) MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes. Scientific Reports 3: Artn 2100.
30. CAST (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. New England Journal of Medicine 321: 406-412.
31. Patel C, Antzelevitch C (2008) Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 5: 585-590.
32. Casis O, Olesen SP, Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69: 658- 665.
33. Durdagi S, Randall T, Chamberlin AC, Duff HJ, Noskov SY (2014) Rehabilitating drug-induced long-QT promoters: In-silico design of hERGneutral cisapride analogues with retained pharmacological activity. BMC Pharmacol Toxicol 15: 14.
34. Payandeh J, Scheuer T, Zheng N, Catterall WA (2011) The crystal structure of a voltage-gated sodium channel. Nature 475: 353-358.
35. Kell DB, Dobson PD, Bilsland E, Oliver SG (2013) The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: What we (need to) know and how we can do so. Drug Discovery Today 18: 218-239.